Elevance Health Inc (ELV · NYSE)

ELV · MARKET VIEW

Market view · as of Aug 10, 2026

Revenue (TTM)
$201.11B
+1.4% YoY
Gross margin
26.0%
EPS (latest q)
$7.45
vs $6.18 est · beat
52-wk position
78.2%
-7.6% vs 52w high · -5.3% 1mo

Price (last ~year)

Elevance Health Inc. (ELV) reported second-quarter 2026 revenue of $50.47 billion and net income of $1.46 billion, marking the company’s fourth consecutive earnings beat. While the firm generated $1.63 billion in free cash flow for the period, year-over-year earnings declined 13.1% despite a 1.4% increase in revenue. The stock closed at $394.20, with a market capitalization of $85.49 billion and an analyst price target of $449.10.

Valuation

Market cap
$85.49B
P/E
17.42
PEG
1.396
P/B
1.905
P/S
0.425
Beta
0.692
Analyst target
$449.1

Quality & returns

Gross margin
26.0%
Operating margin
4.6%
Profit margin
2.5%
ROE
11.1%
ROA
3.8%

Price movement

Last
$394.20
1-month
-5.3%
3-month
+0.7%
RSI (14)
58
vs SMA200
+12.7%
52-wk position
78.2% -7.6% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$50.47B$2.06B$1.46B$2.10B
2026-03-31$50.18B$2.66B$1.76B$2.77B
2025-12-31$49.75B$581.0M$547.0M$987.0M
2025-09-30$50.71B$1.76B$1.19B$2.14B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots